Navigation Links
VetStem Biopharma, Inc. Will Present Data on Two Clinical Conditions and an Industry Overview at the North American Veterinary Regenerative Medicine Association Conference
Date:11/15/2016

VetStem has been a long time supporter of the North American Veterinary Regenerative Medicine Association (NAVRMA), a non-profit industry association formed to foster continued research and distribution of information regarding veterinary regenerative medicine for all species. The 2016 Conference will be held in Amelia Island, Florida from November 17th-20th, where VetStem Biopharma will be a platinum sponsor of the event. Dr Robert Harman, VetStem’s founder and CEO, will be presenting on 3 topics during this event. He will present VetStem’s scientific information on two of their latest projects: Adipose-derived stem cells given intravenously improves epistaxis and objective bronchoscopy scoring in horses with exercise-induced pulmonary hemorrhage and A prospective, randomized, blinded and placebo-controlled efficacy study of intraarticular allogeneic adipose stem cells for the treatment of osteoarthritis in dogs. In addition, Dr. Harman was invited to present an industry overview titled “Evolution of Evidence and Regulation in Veterinary Regenerative Medicine.”

“The opportunity to speak at such a prestigious conference and to be a platinum sponsor is an honor and further recognition by the regenerative medicine community of the value of our scientific and educational contributions to the field of regenerative medicine over the past 14 years. We were here at the birth of this industry, have worked with FDA for many years, and intend to provide evidenced-based products for many years to come” stated Dr Harman.

VetStem has always held the belief that scientific evidence, continuing education, and regulatory guidance are the foundation of developing any new technology. VetStem first pioneered adipose-derived stem cell therapy for use in horses for tendon injuries, as an alternative to euthanasia. Just two years after the first horse was treated, VetStem treated the first cat and dog. In 2007 the first peer-reviewed, randomized, double-blinded, placebo controlled, multi-center study using VetStem therapy was published showing intra-articular injection of autologous adipose derived stem cells in the hip joint of a dog decreased patient discomfort and increased patient functional ability. That same year VetStem brought to market the Genesis Platelet Rich Plasma concentration system, as well as the first formal RACE-approved stem cell credentialing continuing education course.

In 2015, VetStem (now VetStem Biopharma) announced the successful completion and peer-reviewed publication of a pilot efficacy study for allogeneic stem cell therapy (93 dogs, multi-center, blinded, placebo controlled) in support of an FDA INADA. The primary end point was statistically significantly improved. VetStem also entered into a distribution and clinical research agreement with Pall LifeSciences on the V-PET™ platelet enhancement therapy system. The V-PET™ is supported by a JAVMA peer reviewed publication of a two center, double-blinded, randomized study in osteoarthritis in dogs.

VetStem is developing multiple stem cell products for FDA-approval that will provide for therapeutic solutions for difficult-to-treat medical conditions in the dog, cat and horse.

About VetStem Biopharma
VetStem Biopharma is a veterinarian-lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at http://www.prweb.com/releases/2016/11/prweb13838528.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
2. VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
3. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services.
4. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
5. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
6. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
7. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
8. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
9. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
10. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
11. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/2/2019)... , ... October 31, 2019 , ... ... always used to communicating with each other: study managers, principal investigators, supply chain ... if a party is not informed of the latest data, potentially leading to ...
(Date:10/30/2019)... ... October 30, 2019 , ... While using cold plasma to ... at South Dakota School of Mines & Technology are exploring new ways ... cells alive. , If successful, the technique would prove to be a drug-free, ...
(Date:10/29/2019)... ... October 29, 2019 , ... Modality Solutions, ... and cold chain validation workshop at the Biomanufacturing World Summit (BMWS19) Conference, November ... , The Biomanufacturing World Summit brings together pharmaceutical executives, cutting-edge technology ...
(Date:10/22/2019)... , ... October 22, 2019 , ... nQ Medical, Inc. ... School’s 2019 Most Fundable Companies List which was announced at a showcase event yesterday ... million in annual revenue, strong business plans, and impressive near-term growth projections to be ...
Breaking Biology Technology:
(Date:11/14/2019)... ... November 13, 2019 , ... NDA Partners Chairman ... regulatory affairs and program management executive with more than 33 years of regulatory ... the firm as an Expert Consultant. , Robert Peterson has extensive experience ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... Spend Optimizer that improves digital advertising performance up to 25% and reduces cost-per-click ... Cross-Channel Spend Optimizer uses advanced multi-touch attribution (MTA) to predict best advertising outcomes ...
(Date:11/9/2019)... (PRWEB) , ... November 08, 2019 , ... SiteSeer Technologies, ... Acquisitions as a new client and user of SiteSeer. The boutique real estate ... across the U.S. will use SiteSeer to supplement its own analysis of markets. ...
Breaking Biology News(10 mins):